NEWS HIGHLIGHTS
Published Studies Related to Nicardipine
Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. [2009.06]
BACKGROUND: Elevation in cardiac enzymes after percutaneous coronary intervention (PCI) is common and is associated with adverse clinical outcomes. HYPOTHESIS: Administration of intracoronary nicardipine-a calcium channel blocker will reduce cardiac enzyme levels in patients undergoing elective PCI... CONCLUSIONS: In low-risk patients undergoing elective PCI, intracoronary nicardipine administration did not produce a significant cardioprotective effect in reducing postprocedural cardiac enzymes leakage. Copyright (c) 2009 Wiley Periodicals, Inc.
Effect of nicardipine on renal function after robot-assisted laparoscopic radical prostatectomy. [2009.05]
OBJECTIVES: To investigate the renoprotective effect of nicardipine in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALRP) in a prospective trial. Superior visualization of the increasingly performed RALRP requires pneumoperitoneum and extreme head-down tilt, both of which are associated with a decrease in postoperative renal function. Nicardipine causes preferential dilation of the renal arterioles and attenuates renal dysfunction after cardiac surgery... CONCLUSIONS: Continuous infusion of low-dose nicardipine during RALRP seems to offset the deleterious effects of inevitable pneumoperitoneum and extreme head-down tilt on renal function in preserving the eGFR and attenuating the development of renal insufficiency in the immediate postoperative period.
Characterization of functional outcome and quality of life following subarachnoid hemorrhage in patients treated with and without nicardipine prolonged-release implants. [2009.05]
OBJECT: The use of nicardipine prolonged-release implants (NPRIs) is associated with a significant improvement in the therapy of patients suffering from aneurysmal subarachnoid hemorrhage (aSAH) regarding the occurrence and severity of cerebral vasospasm, new infarcts, and functional outcome (FO). Because quality of life (QOL) measurements more reliably seem to describe the patient's true condition, the present study was conducted to assess FO and QOL 1 year after aneurysm rupture in patients with and without NPRIs... CONCLUSIONS: Despite FO improvement in terms of a lower incidence of cerebral vasospasm, new infarcts, morbidity in the treatment of aSAH in patients with NPRIs, a patient's QOL seems to be related to the severity of the aSAH itself.
Use of injectable nicardipine for neurovascular indications. [2009.04]
Injectable nicardipine is increasingly being used to manage neurovascular conditions. To better understand its place in therapy, we conducted an evidenced-based literature review.Although intraarterial nicardipine appears to be promising in aneurysmal subarachnoid hemorrhage, well-designed studies are needed in this setting before its use can be routinely recommended.
The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. [2008.10]
BACKGROUND: Acute hypertension during cardiac surgery can be difficult to manage and may adversely affect patient outcomes. Clevidipine is a novel, rapidly acting dihydropyridine L-type calcium channel blocker with an ultrashort half-life that decreases arterial blood pressure (BP). The Evaluation of CLevidipine In the Perioperative Treatment of Hypertension Assessing Safety Events trial (ECLIPSE) was performed to compare the safety and efficacy of clevidipine (CLV) with nitroglycerin (NTG), sodium nitroprusside (SNP), and nicardipine (NIC) in the treatment of perioperative acute hypertension in patients undergoing cardiac surgery... CONCLUSIONS: CLV is a safe and effective treatment for acute hypertension in patients undergoing cardiac surgery.
Clinical Trials Related to Nicardipine
Evaluation of IV Cardene(Nicardipine)and Labetalol Use in the Emergency Department [Recruiting]
IV Double and Triple Concentrated Nicardipine for Stroke and ICH [Recruiting]
Hypertension (high blood pressure) can often cause neurological worsening in patients with
stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of
nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of
Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The
purpose of this study is to evaluate safety and efficacy of double or triple concentrated
peripheral intravenous (IV) Nicardipine.
Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine [Recruiting]
The aim of this study is to confirm that URAPIDIL is as efficient and as safe as NICARDIPINE
to correct severe hypertension in pre-eclamptic patients.
- efficacy endpoint : mean arterial blood pressure corrected to 105-125 mmHg after 120
min of study drug administration.
- safety endpoints : clinical, biological and ultrasound observation for any side
effect. All infants will be observed in the neonatology unit (during 48h).
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension [Recruiting]
To define the relationship between Cardene I. V. dose, serum concentrations, and blood
pressure reduction in pediatric subjects with hypertension.
NICardipine Neuroprotection in AortiC Surgery (NICNACS) [Not yet recruiting]
Objective
The objective of this study is to discover whether an infusion of nicardipine is able to
reduce the time taken to achieve electrocerebral silence (ECS) during cardiopulmonary bypass
(CPB) for aortic surgery.
Hypothesis
By inhibiting cold-induced cerebral vasoconstriction, nicardipine will maintain cerebral
blood flow and allow more rapid cooling of the brain during CPB. This will manifest as a
reduction in the time taken to achieve ECS and also as a reduction in overall CPB time.
|
